Slingshot members are tracking this event:

Phase 2 results for MGCD265 (glesatinib) in non-small cell lung cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Management Comment "In the ongoing Phase 1b dose expansion trial, glesatinib has demonstrated confirmed partial responses and significant tumor regressions in heavily pre-treated non-small cell lung cancer patients with MET or Axl gene amplification and MET mutations,"
Additional Relevant Details Live Clinical Trials page:
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 16, 2019
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Glesatinib, Mgcd265, Non-small Cell Lung Cancer, Nsclc, Open-label, Phase 2, Met Gene